HomeCompareAEZS vs SPHD

AEZS vs SPHD: Dividend Comparison 2026

AEZS yields 34.97% · SPHD yields 4.30%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AEZS wins by $149.1K in total portfolio value
10 years
AEZS
AEZS
● Live price
34.97%
Share price
$5.72
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$175.6K
Annual income
$26,494.15
Full AEZS calculator →
SPHD
SPHD
● Live price
4.30%
Share price
$49.61
Annual div
$2.14
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.5K
Annual income
$567.37
Full SPHD calculator →

Portfolio growth — AEZS vs SPHD

📍 AEZS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAEZSSPHD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AEZS + SPHD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AEZS pays
SPHD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AEZS
Annual income on $10K today (after 15% tax)
$2,972.03/yr
After 10yr DRIP, annual income (after tax)
$22,520.03/yr
SPHD
Annual income on $10K today (after 15% tax)
$365.92/yr
After 10yr DRIP, annual income (after tax)
$482.26/yr
At 15% tax rate, AEZS beats the other by $22,037.76/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AEZS + SPHD for your $10,000?

AEZS: 50%SPHD: 50%
100% SPHD50/50100% AEZS
Portfolio after 10yr
$101.0K
Annual income
$13,530.75/yr
Blended yield
13.39%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on AEZS right now

AEZS
Analyst Ratings
4
Buy
2
Hold
1
Sell
Consensus: Buy
Altman Z
0.3
Piotroski
1/9
SPHD
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AEZS buys
0
SPHD buys
0
No recent congressional trades found for AEZS or SPHD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAEZSSPHD
Forward yield34.97%4.30%
Annual dividend / share$2.00$2.14
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$175.6K$26.5K
Annual income after 10y$26,494.15$567.37
Total dividends collected$126.6K$5.0K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: AEZS vs SPHD ($10,000, DRIP)

YearAEZS PortfolioAEZS Income/yrSPHD PortfolioSPHD Income/yrGap
1← crossover$14,197$3,496.50$11,130$430.50+$3.1KAEZS
2$19,829$4,639.08$12,357$447.82+$7.5KAEZS
3$27,273$6,055.84$13,687$464.65+$13.6KAEZS
4$36,967$7,784.29$15,126$480.98+$21.8KAEZS
5$49,415$9,860.73$16,682$496.78+$32.7KAEZS
6$65,193$12,318.97$18,362$512.03+$46.8KAEZS
7$84,946$15,189.12$20,174$526.72+$64.8KAEZS
8$109,388$18,496.47$22,127$540.84+$87.3KAEZS
9$139,306$22,260.50$24,230$554.39+$115.1KAEZS
10$175,552$26,494.15$26,493$567.37+$149.1KAEZS

AEZS vs SPHD: Complete Analysis 2026

AEZSStock

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications. The company markets macimorelin under the Macrilen brand name. Aeterna Zentaris Inc. has a license agreement with University Wuerzburg to research, develop, manufacture, and sell a potential COVID-19 vaccine; development, manufacture, and commercialization of the treatment for neuromyelitis optica spectrum disorder; and to develop human 3D intestinal tissue models to study infection biology; and for pre-clinical development towards the potential treatment of Parkinson's disease. It also has a license agreement with Consilient Health Ltd., Novo Nordisk Novo Nordisk Health Care AG, and NK MEDITECH Ltd. for the development and commercialization of macimorelin in the United States and Canada, as well as The University of Sheffield, the United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.

Full AEZS Calculator →

SPHDETF

The Invesco S&P 500 High Dividend Low Volatility ETF (Fund) is based on the S&P 500 Low Volatility High Dividend Index (Index). The Fund will invest at least 90% of its total assets in common stocks that comprise the Index. Standard & Poor's compiles, maintains and calculates the Index, which is composed of 50 securities traded on the S&P 500 Index that historically have provided high dividend yields and low volatility. The Fund and the Index are rebalanced and reconstituted semi-annually, in January and July.

Full SPHD Calculator →
📬

Get this AEZS vs SPHD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AEZS vs SCHDAEZS vs JEPIAEZS vs OAEZS vs KOAEZS vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.